The awareness of the potential impact of CYP2D6 polymorphisms in tamoxifen pharmacokinetics and pharmacodynamics has motivated a series of pharmacogenomic studies, designed to explore the possibility of using CYP2D6 genotyping for predicting clinical outcomes in breast cancer patients receiving tamoxifen. This evidence concerns the gene CYP2D6 and breast cancer.